Genitourinary Cancers Symposium Annual Meeting Coverage

Radium-223 Use in mCRPC Differs By Race

Radium-223 Use in mCRPC Differs By Race

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.

Newer mCRPC Drugs Led to Longer Survival in African American Patients

Newer mCRPC Drugs Led to Longer Survival in African American Patients

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

In a small phase 2 study of overweight men with recurrent prostate cancer, consuming less than 20 grams of carbohydrates a day resulted in profound weight loss.

Sign Up for Free e-newsletters